Biotech Consolidation Heats Up as argenx Seeks to Bolster Immunology Portfolio The pharmaceutical industry's consolidation trend continues to gain momentum with biotechnology giant argenx announcing its intention to acquire Forte Biosciences for $2.
2 billion. This strategic move marks the latest example of major players expanding their capabilities and addressing pressing medical needs through targeted acquisitions.
argenx's pursuit of Forte Biosciences' flagship asset, FB102, an anti CD122 antibody, highlights the growing importance of immunology in modern medicine.